216 related articles for article (PubMed ID: 22403636)
1. Single cycle structure-based humanization of an anti-nerve growth factor therapeutic antibody.
Covaceuszach S; Marinelli S; Krastanova I; Ugolini G; Pavone F; Lamba D; Cattaneo A
PLoS One; 2012; 7(3):e32212. PubMed ID: 22403636
[TBL] [Abstract][Full Text] [Related]
2. Dissecting NGF interactions with TrkA and p75 receptors by structural and functional studies of an anti-NGF neutralizing antibody.
Covaceuszach S; Cassetta A; Konarev PV; Gonfloni S; Rudolph R; Svergun DI; Lamba D; Cattaneo A
J Mol Biol; 2008 Sep; 381(4):881-96. PubMed ID: 18635195
[TBL] [Abstract][Full Text] [Related]
3. Purification, crystallization, X-ray diffraction analysis and phasing of a Fab fragment of monoclonal neuroantibody alphaD11 against nerve growth factor.
Covaceuszach S; Cassetta A; Cattaneo A; Lamba D
Acta Crystallogr D Biol Crystallogr; 2004 Jul; 60(Pt 7):1323-7. PubMed ID: 15213405
[TBL] [Abstract][Full Text] [Related]
4. Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor.
Eibl JK; Strasser BC; Ross GM
Neurochem Int; 2012 Dec; 61(8):1266-75. PubMed ID: 23103525
[TBL] [Abstract][Full Text] [Related]
5. Generation of a high-fidelity antibody against nerve growth factor using library scanning mutagenesis and validation with structures of the initial and optimized Fab-antigen complexes.
La Porte SL; Eigenbrot C; Ultsch M; Ho WH; Foletti D; Forgie A; Lindquist KC; Shelton DL; Pons J
MAbs; 2014; 6(4):1059-68. PubMed ID: 24830649
[TBL] [Abstract][Full Text] [Related]
6. Neutralization of NGF-TrkA receptor interaction by the novel antagonistic anti-TrkA monoclonal antibody MNAC13: a structural insight.
Covaceuszach S; Cattaneo A; Lamba D
Proteins; 2005 Feb; 58(3):717-27. PubMed ID: 15625712
[TBL] [Abstract][Full Text] [Related]
7. Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer?
Bannwarth B; Kostine M
Drugs; 2017 Sep; 77(13):1377-1387. PubMed ID: 28660479
[TBL] [Abstract][Full Text] [Related]
8. Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis.
von Loga IS; El-Turabi A; Jostins L; Miotla-Zarebska J; Mackay-Alderson J; Zeltins A; Parisi I; Bachmann MF; Vincent TL
Ann Rheum Dis; 2019 May; 78(5):672-675. PubMed ID: 30862648
[TBL] [Abstract][Full Text] [Related]
9. A fully caninised anti-NGF monoclonal antibody for pain relief in dogs.
Gearing DP; Virtue ER; Gearing RP; Drew AC
BMC Vet Res; 2013 Nov; 9():226. PubMed ID: 24206926
[TBL] [Abstract][Full Text] [Related]
10. In Vitro and In Vivo Characterization of a Fully Felinized Therapeutic Anti-Nerve Growth Factor Monoclonal Antibody for the Treatment of Pain in Cats.
Gearing DP; Huebner M; Virtue ER; Knight K; Hansen P; Lascelles BD; Gearing RP; Drew AC
J Vet Intern Med; 2016 Jul; 30(4):1129-37. PubMed ID: 27306920
[TBL] [Abstract][Full Text] [Related]
11. PG110, A Humanized Anti-NGF Antibody, Reverses Established Pain Hypersensitivity in Persistent Inflammatory Pain, but not Peripheral Neuropathic Pain, Rat Models.
Djouhri L
Pain Med; 2016 Nov; 17(11):2082-2094. PubMed ID: 26917622
[TBL] [Abstract][Full Text] [Related]
12. Affinity maturation, humanization, and co-crystallization of a rabbit anti-human ROR2 monoclonal antibody for therapeutic applications.
Goydel RS; Weber J; Peng H; Qi J; Soden J; Freeth J; Park H; Rader C
J Biol Chem; 2020 May; 295(18):5995-6006. PubMed ID: 32193207
[TBL] [Abstract][Full Text] [Related]
13. Analgesic effects of nerve growth factor-directed monoclonal antibody on diabetic neuralgia in an animal model.
Dong X; Li H; Pei M; Tan J; Chen G; Li S; Xie Z; Wang Q; Wang G; Chen YL; Wang C
FEBS Open Bio; 2022 Jul; 12(7):1325-1335. PubMed ID: 35417079
[TBL] [Abstract][Full Text] [Related]
14. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?
Bannwarth B; Kostine M
Drugs; 2014 Apr; 74(6):619-26. PubMed ID: 24691709
[TBL] [Abstract][Full Text] [Related]
15. Tanezumab in the treatment of chronic musculoskeletal conditions.
Jayabalan P; Schnitzer TJ
Expert Opin Biol Ther; 2017 Feb; 17(2):245-254. PubMed ID: 27936977
[TBL] [Abstract][Full Text] [Related]
16. Development and preclinical characterization of a humanized antibody targeting CXCL12.
Zhong C; Wang J; Li B; Xiang H; Ultsch M; Coons M; Wong T; Chiang NY; Clark S; Clark R; Quintana L; Gribling P; Suto E; Barck K; Corpuz R; Yao J; Takkar R; Lee WP; Damico-Beyer LA; Carano RD; Adams C; Kelley RF; Wang W; Ferrara N
Clin Cancer Res; 2013 Aug; 19(16):4433-45. PubMed ID: 23812669
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of nerve growth factor and discovery of tanezumab, an anti-nerve growth factor antibody and pain therapeutic.
Hefti F
Pharmacol Res; 2020 Apr; 154():104240. PubMed ID: 31026504
[TBL] [Abstract][Full Text] [Related]
18. Antibody Fragments Humanization: Beginning with the End in Mind.
Aubrey N; Billiald P
Methods Mol Biol; 2019; 1904():231-252. PubMed ID: 30539473
[TBL] [Abstract][Full Text] [Related]
19. Long-term analgesic effect of a single dose of anti-NGF antibody on pain during motion without notable suppression of joint edema and lesion in a rat model of osteoarthritis.
Ishikawa G; Koya Y; Tanaka H; Nagakura Y
Osteoarthritis Cartilage; 2015 Jun; 23(6):925-32. PubMed ID: 25677108
[TBL] [Abstract][Full Text] [Related]
20. Antibody humanization by redesign of complementarity-determining region residues proximate to the acceptor framework.
Hanf KJ; Arndt JW; Chen LL; Jarpe M; Boriack-Sjodin PA; Li Y; van Vlijmen HW; Pepinsky RB; Simon KJ; Lugovskoy A
Methods; 2014 Jan; 65(1):68-76. PubMed ID: 23816785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
